Agenus announces publication in the journal of clinical oncology highlighting data from botensilimab plus balstilimab in relapsed/refractory metastatic sarcomas

Lexington, mass.--(business wire)--agenus inc. (nasdaq: agen), a leader in immuno-oncology, today announced publication in the journal of clinical oncology showcasing data from its study of botensilimab (bot) in combination with balstilimab (bal) in patients with relapsed/refractory (r/r) metastatic sarcomas. these findings further reinforce the consistency of the bot/bal combination, which has already shown activity and a favorable safety profile across both multiple “warm and cold” tumor type.
AGEN Ratings Summary
AGEN Quant Ranking